文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

肾上腺素治疗而非ROSC时间与心脏骤停患者肠损伤相关

Epinephrine treatment but not time to ROSC is associated with intestinal injury in patients with cardiac arrest.
PubMed 文献 · Resuscitation · 2020-06-06
一句话结论心脏骤停复苏后患者中,肾上腺素累积剂量与肠损伤标志物iFABP升高及6个月死亡率增加相关,而ROSC时间无此关联。

该单中心研究纳入52例心脏骤停后ROSC并收入内科ICU的患者,入院时检测循环肠脂肪酸结合蛋白(iFABP)。结果显示iFABP水平与肾上腺素剂量相关(R=0.32,p<0.05),与ROSC时间无关;接受≥3 mg肾上腺素者40%出现iFABP>1500 pg/mL,显著高于<3 mg者的10.5%(p<0.05),且该高水平与死亡率大幅增加相关(HR 4.87,95%CI 1.95-12.1;p<0.001)。iFABP可独立于ROSC时间和SAPS II评分预测死亡,但与神经功能结局无关。提示肾上腺素累积剂量可能与肠损伤及远期死亡相关。

要点

  • 心脏骤停ROSC后患者中,肾上腺素累积剂量与iFABP水平相关(R=0.32;p<0.05),而ROSC时间与iFABP无关。
  • 接受≥3 mg肾上腺素者40%出现iFABP>1500 pg/mL,显著高于<3 mg者的10.5%(p<0.05)。
  • iFABP>1500 pg/mL与死亡率大幅增加相关(HR 4.87,95%CI 1.95-12.1;p<0.001)。
  • 幸存者iFABP水平(234 pg/mL,IQR 90-399)低于非幸存者(283 pg/mL,IQR 86-11500;p<0.05)。
  • iFABP预测死亡独立于ROSC时间和SAPS II评分,但与神经功能结局无关。

适用人群与场景

  • 心脏骤停后实现自主循环恢复(ROSC)并收入内科ICU的患者,共52例。

诊断标准与关键阈值

  • iFABP血浆水平>1500 pg/mL被定义为高水平,该阈值与死亡率大幅增加相关(HR 4.87,95%CI 1.95-12.1;p<0.001)。

研究设计与关键结果

  • 研究类型:单中心研究,纳入52例CA后ROSC患者,年龄64(49.8-73.8)岁,男性76.9%。
  • 6个月时50%患者死亡,38.5%患者脑功能分类(CPC)评分为1-2。
  • 幸存者iFABP水平(234 pg/mL,IQR 90-399)低于非幸存者(283 pg/mL,IQR 86-11500;p<0.05)。
  • iFABP水平与ROSC时间无关,但与肾上腺素剂量相关(R=0.32;p<0.05)。
  • 接受≥3 mg肾上腺素者40%出现iFABP>1500 pg/mL,而<3 mg者仅10.5%(p<0.05)。
  • iFABP>1500 pg/mL与死亡率大幅增加相关(HR 4.87,95%CI 1.95-12.1;p<0.001)。
  • iFABP预测死亡率独立于ROSC时间和疾病严重程度评分SAPS II;iFABP与神经功能结局无关。

证据类型、等级与局限

  • 证据类型:单中心研究。
  • 局限:原文报告为小型单中心研究(small, single centre study)。

对床旁实践的改变

  • 作者认为,心脏骤停患者中肾上腺素累积剂量与肠损伤生物标志物升高及6个月死亡率相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Current guidelines suggest the use of epinephrine in patients with cardiac arrest (CA). However, evidence for increased survival in good neurological condition is lacking. In experimental settings, epinephrine-induced impairment of microvascular flow was shown. The aim of our study was to analyze the association between epinephrine treatment and intestinal injury in patients after CA.

METHODS: We have included 52 patients with return of spontaneous circulation (ROSC) after CA admitted to our medical intensive care unit (ICU). Blood was taken on admission and levels of circulating intestinal fatty acid binding protein (iFABP) were analyzed.

RESULTS: Patients were 64 (49.8-73.8) years old and predominantly male (76.9%). After six months, 50% of patients died and 38.5% of patients had a cerebral performance category (CPC)-score of 1-2. iFABP levels were lower in survivors (234 IQR 90-399 pg/mL) as compared to non-survivors (283, IQR 86-11500 pg/mL; p < 0.05). Plasma levels of iFABP were not associated with time to ROSC but correlated with epinephrine-dose (R = 0.32; p < 0.05). 40% of patients receiving ≥3 mg of epinephrine as compared to 10.5% of patients treated with <3 mg (p < 0.05) developed iFABP plasma levels >1500 pg/mL, which was associated with dramatically increased mortality (HR4.87, 95%CI 1.95-12.1; p < 0.001). iFABP levels predicted mortality independent from time to ROSC and the disease severity score SAPS II. In contrast to mortality, iFABP plasma levels were not associated with neurological outcome.

CONCLUSIONS: In this small, single centre study, cumulative dose of epinephrine used in cardiac arrest patients was associated with an increase in biomarker indicative of intestinal injury and 6-month mortality.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Krychtiuk KA, Richter B, Lenz M, et al. Epinephrine treatment but not time to ROSC is associated with intestinal injury in patients with cardiac arrest. Resuscitation. 2020. PMID: 32522698. doi:10.1016/j.resuscitation.2020.05.046

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。